Objective:To analyze the risk factors of slow coronary flow and therapeutic effect of diltiazem. Methods:Fifty-seven coronary arteriongraphy imageology documents are analyzed retrospectively. Thirty-one patients with coronary slow flow but without coronary disease confirmed by coronary angiography were selected as slow coronary flow group,and 26 patients,without coronary slow coronary flow and coronary disease,confirmed by coronary angiography as well,were selected as control group. Clinical features,the efficacy of diltiazem on coronary slow flow and the MACE outcomes were investigated in the two groups by t test and chisquared test Results:There was no significantly difference between the two groups in gender,age,heart rate,blood pressure,fasting plasma glucose,blood lipid,and coagulation time. However,levels of RBC and uric acid were significantly higher in the slow coronary flow group compared with the control group. Moreover,significant higher uric acid was observed in subjects with slow coronary flow after adjustment of age,sex,hypertension,diabetes mellitus,dyslipidemia and smoking status. None cardiovascular event occurred on the patients in slow coronary flow group. However,patients treated with diltiazem felt chest complaint lighten than those in the control group. Conclusion:High uric acid palys an important role in the pathogenesis of slow coronary flow. Diltiazem as an adjunct may further lighten chest complaint in patients with slow coronary flow.